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Abstract: 
Extracts from the seeds of milk thistle, Silybum marianum, are known commonly as silibinin and silymarin and 
possess anticancer actions on human prostate carcinoma in vitro and in vivo. Seven distinct flavonolignan 
compounds and a flavonoid have been isolated from commercial silymarin extracts. Most notably, two pairs of 
diastereomers, silybin A and silybin B and isosilybin A and isosilybin B, are among these compounds. In 
contrast, silibinin is composed only of a 1:1 mixture of silybin A and silybin B. With these isomers now isolated 
in quantities sufficient for biological studies, each pure compound was assessed for antiproliferative activities 
against LNCaP, DU145, and PC3 human prostate carcinoma cell lines. Isosilybin B was the most consistently 
potent suppressor of cell growth relative to either the other pure constituents or the commercial extracts. 
Isosilybin A and isosilybin B were also the most effective suppressors of prostate-specific antigen secretion by 
androgen-dependent LNCaP cells. Silymarin and silibinin were shown for the first time to suppress the activity 
of the DNA topoisomerase II gene promoter in DU 145 cells and, among the pure compounds, isosilybin B was 
again the most effective. These findings are significant in that isosilybin B composes no more than 5% of 
silymarin and is absent from silibinin. Whereas several other more abundant flavonolignans do ultimately 
influence the same end points at higher exposure concentrations, these findings are suggestive that extracts 
enriched for isosilybin B, or isosilybin B alone, might possess improved potency in prostate cancer prevention 
and treatment. 
 
Article: 
Introduction 
Prostate cancer is the most commonly diagnosed invasive malignancy and second leading cause of cancer death 
in American men, accounting for an estimated 220,900 new cases and 28,900 deaths in the United States in 
2003 (1). Dietary factors have been associated with increased prostate cancer incidence, thereby leading to 
studies of dietary modification and supplementation as preventative approaches (2; reviewed in ref. 3). 
Naturally occurring polyphenolic antioxidants are recognized as one of the most effective classes of cancer 
preventive agents (4–8), as they exhibit little or no systemic toxicity (9) and because oxidative stress is a known 
contributor to carcinogenesis (10). 
 
Over the last several years, extracts from the seeds of milk thistle [Silybum marianum (L.) Gaertn. (Asteraceae)] 
have shown efficacy in arresting human prostate carcinoma proliferation in a number of in vitro and in vivo 
preclinical models. This traditional botanical agent has been used since antiquity as a hepatoprotectant against 
Amanita mushroom poisoning and oxidative damage by xenobiotics, particularly in Europe (11). Interest in its 
utility in cancer followed a report in 1994 showing its effectiveness against tumor progression in a rodent skin 
cancer model (12). Collectively, the milk thistle flavonolignan mixtures silymarin and silibinin have been 
shown to possess significant antiproliferative effects in cultured cancer cells (13), antiproliferative and 
antiangiogenic 
activities in vivo in a number of rodent and human cancer models (14, 15), and synergy with cytotoxic 
chemotherapeutics in vitro and in xenografts of human prostate and ovarian cancer (16, 17). Therefore, these 
and other chemopreventive agents have become the focus of emerging interest in cancer treatment (18). 
 
The proximal molecular target of milk thistle compounds has proven evasive, but a number of cancer cell 
signaling pathways are influenced by these agents that consequently suppress mitogenic and cell survival 
programming (7). Silibinin and silymarin inhibit extracellular signal-regulated kinase (ERK1/2) activation in 
prostate carcinoma cells, which is associated with decreased [
125
I]-EGF ligand binding (19). Silibinin also 
inhibits the constitutive activation of nuclear factor B in DU145 cells by reducing p65 and p50 levels, 
increasing I B levels, and decreasing I B kinase activity (20). Silibinin stimulates production by PC3 cells of the 
insulin-like growth factor binding protein, IGFBP-3, and antisense IGFBP-3 oligonucleotides attenuate the 
growth inhibitory effects of silibinin (21). Silibinin influences the cell cycle to cause G1 arrest in many but not 
all cases. Silibinin treatment of LNCaP or DU145 cells causes hypophosphorylation of Rb/p107 and Rb2/p130 
and enhanced Rb-E2F association with a concomitant decrease in abundance of several E2F family members 
(22, 23). In LNCaP cells, silibinin reduces levels of cyclin D1, CDK4, and CDK6, while inducing p21 
Cip1
 and 
p27
Kip1
, which causes G1 growth arrest and cellular differentiation but little indication of apoptosis 
(24). Longer treatment of some cancer cell lines with silymarin or silibinin will ultimately trigger apoptosis, and 
silibinin was shown recently to reduce mRNA levels of survivin, an apoptotic inhibitor, in bladder transitional 
carcinoma cells (25). The most direct effect of milk thistle extracts observed to date has been the in vitro 
displacement by silymarin of radiolabeled 17ß-estradiol from ERß but not ER at concentrations similar to those 
causing cancer cell growth arrest (26). However, the functional significance of this in vitro observation on 
prostate carcinoma survival and growth remains unknown. 
 
Understanding how compounds from milk thistle affect cell cycle and cell signaling to arrest cancer cell growth 
has been confounded by the lack of standardized nomenclature for the crude plant extracts and their individual 
pure compounds (27). Silymarin and silibinin are the most common forms of milk thistle extract sold 
commercially and the terms are often used interchangeably, albeit incorrectly (27). Recently, the Research 
Triangle Institute Natural Products Laboratory isolated and purified from silymarin (crude milk thistle extract) a 
series of seven distinct flavonolignans and one flavonoid (28). Silibinin has now been shown to be a 1:1 mixture 
of two stereoisomers, denoted silybin A and silybin B. Of greatest significance is that two other regioisomers 
have been isolated as well that possess the same molecular mass, isosilybin A and isosilybin B (Fig. 1). These 
four compounds share the same chemical formula but differ in structure only with respect to the stereochemical 
positions of the terminal aryl(3-methoxy-4-hydroxyphenyl) and hydroxymethyl groups at the and ß carbons 
(Fig. 1). Isolation of these two pairs of diastereomers and their stereochemical assignments has also been 
accomplished and confirmed independently (29). Interestingly, evidence had existed as early as 1979 (30) to 
indicate that silybin and isosilybin were each mixtures of diastereomers, but pure reference standards and 
experimental quantities had not been available previously for biological studies. The resolution and purification 
of each of these compounds in milligram quantities now permits a dissection of the molecular actions of milk 
thistle extracts in prostate cancer suppression. The current report represents a first step in addressing the 
hypothesis of whether each individual milk thistle compound possesses distinct or overlapping biochemical 
actions that contribute to the overall, broad anticancer activity of the natural product extracts. 
 
A number of end points were investigated that result from the antiproliferative effects of each milk thistle 
compound, including prostate cancer cell growth suppression, cell cycle distribution, as well as the suppression 
of prostate-specific antigen (PSA) secretion, and DNA topoisomerase II (topo II ) promoter activity. Topo II , a 
nuclear enzyme involved in DNA replication, chromosomal segregation, and recombination, is absolutely 
required for cellular proliferation, as its DNA decatenation activity is essential to successful chromosomal 
segregation (31). A recent meta-analysis of gene expression data sets from normal versus cancerous human 
tissue specimens revealed that topo II is one of the most commonly activated genes across a large majority of 
human cancers (32). The current report details the first demonstration of suppression of topo II gene 
expression by either crude milk thistle extracts or pure compounds. Silibinin had also been shown to decrease in 
androgen-dependent LNCaP prostate carcinoma cells the secreted levels of PSA, a clinical diagnostic serum 
marker for monitoring the presence and progression of prostate cancer (33, 34). This diagnostic tool provided us 
with a well-characterized end point for further dissection of the action of individual pure milk thistle 
compounds. 
 
 
Figure 1. Chemical components of milk thistle extracts (S. marianum). These eight compounds have been  
identified in three milk thistle extracts available commercially as silymarin (28). Composition of each extract is  
listed in Table 1. The seven flavonolignan compounds share a formula weight of 482.1. Taxifolin, also called  
dihydroquercetin, is the only flavonoid detected in commercial silymarin products. Silibinin, thought previously  
to be a single compound, is known now to be a 1:1 mixture of the diastereomers, silybin A and silybin B. 
 
 
NOTE: Note that silymarin product composition totals are <100%; each of these products are labeled as 70% 
to 80% silymarin with the remainder consisting of uncharacterized polyphenols and aliphatic fatty acids 
such as oleic and palmitic acids. 
Materials and Methods 
Isolation of reference standards from silymarin  
Preparative high-performance liquid chromatography (HPLC) was used to isolate flavonolignans from 
silymarin (Madaus AG, Cologne, Germany) as described previously (28). Silymarin was obtained also from 
Aldrich (Milwaukee, WI) and Indena SpA (Rome, Italy), and silibinin was obtained from Sigma (St. Louis, 
MO). 
 
For studies involving silibinin, the diastereomeric mixture of silybin A and silybin B, molar calculations were 
employed as if the mixture was a single compound with a formula weight of 482.1. For experiments involving 
silymarin, the crude mixture of eight polyphenolic compounds, molar concentrations are expressed based on a 
formula weight of 482.1 (the formula weight common to each of the seven flavonolignans; the 1.6-2.2% 
contribution of the smaller taxifolin compound was considered negligible.). These molar calculations are 
recognized as imprecise (27) but are presented here as such to enable comparison with previous literature on the 
biological effects of these mixtures. It is suggested in the future that molar calculations be reserved for the pure 
milk thistle compounds and that w/v concentrations be employed when referring to silibinin or silymarin. 
 
Analysis of silymarin and silibinin 
HPLC analyses were done with a Star Chromatography Workstation (version 5.5.1; Varian, Inc., Walnut Creek, 
CA) at a flow rate of 1 mL/min using Varian ProStar 210 pumps with a YMC ODS-A column (S 5 µm, 120 Å, 
4.6 x 150 mm; Waters Co., Milford, MA). Signals were monitored at UV 280 nm using a Varian ProStar 330 
PDA detector, and all injections of reference standards, silymarin, and silibinin were of 50 µL by a Varian 
ProStar 410 autosampler. A quality control standard was used to monitor the consistency of the 
chromatographic analyses by preparing a solution of 0.100 mg/mL biochanin A (Aldrich) in DMSO (DMSO-
B). All standards and study materials were prepared in DMSO-B, and the measured concentration of biochanin 
A did not vary more than ±2% in all determinations. To prepare the standard curves (Supplementary Fig. S 1), 
stock solutions of the reference standards were prepared in DMSO-B and serially diluted to concentrations of 
0.50, 0.20, 0.050, and 0.0125 mg/mL; the absolute concentration of each standard in DMSO-B was calculated 
based on the purity of each reference standard (range, >87% to >99% pure). The R
2
 value for each standard 
curve was >0.99. To verify the presence and confirm the retention time of each of the reference standards in the 
silymarin and silibinin samples, one of the silymarin samples was added to each standard in turn, and the 
observed change in peak area for a distinct peak was observed by HPLC. 
 
Supplementary Fig. S2 illustrates the retention time of each of the reference standards and biochanin A in one 
of the silymarin samples (Indena). Stock solutions of the silymarin samples and silibinin were prepared at 12.0 
mg/mL in DMSO-B, and each was diluted with DMSO-B to a concentration of 1.2 mg/mL for analysis. The 
concentration of the compounds in the silymarin and silibinin samples was calculated from the measured area 
under the peak correlating to each reference standard and extrapolated using the equation for the standard curve 
of that particular standard. 
Cell culture 
Frozen tumor cell stocks were obtained from the American Type Culture Collection (Manassas, VA): LNCaP 
(CRL-1740, an androgen-dependent line derived from a lymph node metastasis of prostate adenocarcinoma), 
DU145 (HTB-81, an androgen-independent line derived from a central nervous system metastasis of prostate 
adenocarcinoma), and PC-3 (CRL-1435, an androgen-independent line derived from a bone metastasis of 
prostate adenocarcinoma). All cell lines were cultured in RPMI 1640 (Life Technologies/Invitrogen, Carlsbad, 
CA) supplemented with 10% (v/v) fetal bovine serum (HyClone, Logan, UT), 100 units/mL penicillin G, and 
100 µg/mL streptomycin sulfate and incubated in a humidified 37°C/5% CO2 incubator. Cells were maintained 
in a logarithmic growth state by subculturing every other day at an initial density of 1 x 10
6
 cells per 75 cm
2
 
flask in 30 mL medium. 
 
Cell survival and flow cytometry assays 
Logarithmically growing prostate carcinoma cells were seeded at 5 x 10
4
 per well of 24-well plates in 0.5 mL of 
supplemented RPMI 1640 and allowed to attach to substrate overnight. The following day, stock solutions of 
silibinin, silymarin, or pure milk thistle compounds were prepared in DMSO at 50 mmol/L and diluted into 
RPMI 1640 at twice the intended final concentration of 30, 60, or 90 µmol/L. A 0.5-mL aliquot of each 
compound in medium, or DMSO at 0.2% (v/v), was added to each well (in triplicate for each final 
concentration). Cells were permitted to grow for 72 hours at which time 10 µL of the mitochondrial 
dehydrogenase substrate, WST-8 [(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4- disulfophenyl)-2H-
tetrazolium, monosodium salt, in combination with phenazine methosulfate; Cell Counting Kit-8, Dojindo, 
Gaithersburg, MD] was added to each well and incubated 1 to 2 hours further. Cell-free wells of medium were 
incubated similarly to correct for nonenzymatic hydrolysis of the substrate to its formazan product. 
Mitochondrial respiratory activity was quantified by spectrophotometry at 450 nm using a Tecan Ultra 
microtiter plate reader (Tecan US, Research Triangle Park, NC) and cellular survival expressed as a percentage 
relative to corrected control values. 
 
Cell cycle distribution of DU145 cells (1 x 10
5
 cells per 60-mm tissue culture plate) treated with silibinin or 
pure compounds was determined after propidium iodide staining by fluorescence-activated cell sorting (FACS) 
analysis at the Duke University Comprehensive Cancer Center Cell Sorting Facility (Durham, NC). 
Topoisomerase II promoter-reporter transfections and reporter activity assays. Logarithmically proliferating 
DU145 cells were plated at 4 x 10
4
 cells per well in 12-well tissue culture plates and allowed to adhere for 5 to 
6 hours in a humidified 37°C/5% CO2 incubator. Cells were transiently transfected with the human topo II gene 
promoter-reporter construct -562TOP2LUC (35) using 0.5 g DNA per well and 3:1 GeneJuice (EMD 
Biosciences/Novagen, Madison, WI) transfection reagent/DNA ratio according to manufacturer's instructions. 
Cells were incubated with the transfection mixture overnight ( 16 hours). Subsequently, purified flavonolignans, 
taxifolin, silibinin, silymarin (all dissolved in DMSO) or vehicle alone were diluted in complete medium at a 3x 
stock concentration and added to transiently transfected cells in triplicate to final concentrations of 30 and 60 
µmol/L. In studies to compare relative potencies of silybin A, silybin B, isosilybin A, and isosilybin B, 
compounds were tested in triplicate using final concentrations of 30, 60, 90, and 120 µmol/L. Cells were 
incubated further for 24 hours before harvest. 
 
After harvesting, cells were assayed for luciferase enzymatic activity using the Enhanced Luciferase Assay Kit 
(BD Biosciences PharMingen, San Diego, CA) according to manufacturer's instructions with a dual-injector 
Monolight 3010 luminometer (PharMingen). Forty microliters of lysate were assayed and triplicate points 
averaged and reported with their respective SDs. In initial experiments, a pCMV plasmid encoding ß-
galactosidase activity (pCMVß, BD Biosciences Clontech, Palo Alto, CA) was used as internal control for 
transfection activity but proved an inadequate one, as it was activated by some flavonolignans and suppressed 
by others. Therefore, subsequent transfection results were expressed as total luciferase light units and repeated 
at least thrice to assure uniformity and confirm the rank order of compound potency. 
 
Western immunoblotting for secreted prostate-specific antigen 
LNCaP cells were plated at a density of 3 x 10
5
 cells per 60-mm dish containing each purified flavonolignan or 
silibinin at final concentrations of 0, 15, 30, 60, and 90 µmol/L. After 24 hours of exposure, the medium was 
replaced with serum-free medium containing the corresponding flavonolignan or silibinin at the same 
concentrations. Cells were incubated 48 hours further and the conditioned medium was collected from each 
sample. Sixty microliters of conditioned media for each sample were resolved by 12% SDS-PAGE and proteins 
transferred onto polyvinylidene difluoride membranes (Amersham Biosciences Co., Piscataway, NJ) by semidry 
electroblotting. Blots were blocked with 5% nonfat dry milk in PBS for 15 minutes and the membranes were 
incubated with primary antibody (goat antihuman PSA, C-19, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) 
at a 1:500 dilution in 2.5% milk in PBS containing 0.05% Tween 20 (PBST) overnight at 4°C with rocking. 
After washing 3x 10 minutes in PBST, blots were incubated with rabbit anti-goat IgG-horseradish peroxidase 
conjugate (1:500) secondary antibody (Bio-Rad Laboratories, Hercules, CA) in PBST with 2.5% milk for 2 
hours at room temperature. After washing membranes in PBST as described above, the blots were incubated 
with Enhanced Chemiluminescence Plus Western Blotting Detection Reagent (Amersham Biosciences) and 
PSA signals were detected using a Storm 860 imaging system (Amersham Biosciences). 
 
Statistical analysis 
Group means were assessed relative to vehicle controls by one-way ANOVA followed by a multiple 
comparison post-test (Bonferroni's correction) using Prism v3.02 software (GraphPad Software, Inc., San 
Diego, CA). 
 
Results 
Composition of commercial milk thistle extracts 
HPLC analysis using reference standards showed clearly that silibinin from Sigma was exclusively an equal 
mixture of silybin A and silybin B and was devoid of any of the five other flavonolignans or taxifolin (ref. 28; 
Table 1). In contrast, each commercial silymarin extract contained all eight compounds in varying but relatively 
constant amounts (Table 1). Of note, silymarin, but not silibinin, contained the two other flavonolignans most 
relevant in this report, isosilybin A and isosilybin B. Among silymarin products, the only large difference 
observed was the greater amount of silydianin in the Indena and Madaus extracts relative to that from Aldrich. 
As shown below in the cellular growth inhibition assays, silydianin alone was a relatively inactive component. 
 
Isosilybin B exhibits preferential growth inhibition of hormone-independent DU145 human prostate 
carcinoma cells 
As a first test of the individual activities of each of the four milk thistle flavonolignans, DU145 cells were 
exposed to each compound at 30, 60, and 90 µmol/L and cell growth assessed after 3 days using the 
mitochondrial succinate dehydrogenase substrate, WST-8. The activity of each compound was also compared 
with that of the other three flavonolignans (silychristin, isosilychristin, and silidianin) as well as the flavonoid, 
taxifolin. 
 
The most significant finding (Table 2) was that isosilybin A and isosilybin B were the only compounds capable 
of significant growth inhibition in DU145 cells at 30 µmol/L after a 72-hour exposure, with isosilybin B 
ranking as the most potent. Silybin A, silybin B, and silibinin had no growth inhibitory activity at this 
concentration. Moreover, the three silymarin extracts were also devoid of activity with the exception of 20% 
growth suppression by the Madaus extract. This observation is notable in that silibinin, well known for its in 
vivo activity against DU145 xenografts (14), was without effect at a concentration where isosilybin A and 
isosilybin B produced 37.5% and 68.9% growth inhibition, respectively. Of course, higher concentrations 
produced similar growth inhibition among the four major flavonolignans, with silybin B being the least 
efficacious. A direct comparison with silymarin is somewhat complicated by the fact that it contains all eight of 
the compounds, as a crude extract, along with other fatty acids and polyphenols. However, on a mass basis, it is 
clear that isosilybin B was more efficacious than any of the three silymarin preparations or silibinin (Fig. 2). 
This trend was also observed with isosilybin A and silybin A in DU145 cells. Because most studies on milk 
thistle extract effectiveness in prostate cancer in vitro and in vivo have employed either mixture (silibinin or 
silymarin), it is notable that three of the four major flavonolignans given alone exhibited substantially greater 
efficacy in the DU145 growth inhibition assay. Moreover, a clear rank order of potency emerged from this 
study: isosilybin B > isosilybin A > silybin A > silybin B. It should be stressed that each of these compounds 
share the same chemical formula and structure with the exception of the stereochemical positions of the 
terminal aryl(3- methoxy-4-hydroxyphenyl) and hydroxymethyl groups at the and ß carbons (Fig. 1). 
 
NOTE: Results are presented as mean percent survival ± SD (n = 3) relative to vehicle controls. The original 
number of cells plated exhibited a substrate conversion rate of 11 % to 15% that of 3 -day growth controls, 
such that survival values in this range indicate 100% growth inhibition. 
* Statistically significant differences from DMSO controls (P < 0.001).  
* Statistically significant differences from DMSO controls (P < 0.05). 
* Statistically significant differences from DMSO controls (P < 0.01). 
 
 
 
 
 
Figure 2. Isosilybin B is more potent than commercial milk thistle extracts in inhibiting the growth of DU145  
prostate carcinoma cells. Data selected from the growth inhibitory experiments in Table 2 (WST-8 reduction  
after 72 hours of exposure to compounds/extracts) is depicted here graphically to illustrate the potency of pure  
isosilybin B relative to silymarin or silibinin. 
 
 
In other experiments (data not shown), the potency of the compounds increased as DU145 cell density 
decreased (and, therefore, as a function of population growth fraction increasing). Under such conditions, 50% 
growth inhibition was observed with as little as 5 µmol/L isosilybin B, although the rank order of potency 
remained unchanged. 
 
Isosilybin B also inhibits cell growth in androgen-independent PC3 and androgen-dependent LNCaP 
human prostate carcinoma cells 
 In parallel experiments using PC3 cells (Table 2), isosilybin B and silybin B exhibited the greatest growth 
inhibition at 30 µmol/L, but there was less distinction among the compounds than in DU145 cells. One notable 
exception to DU145 cells was that the silibinin and silymarin mixtures were comparable in activity to the pure 
flavonolignans against PC3 cells. 
 
In androgen-dependent LNCaP cells grown in complete media, isosilybin B was also the most effective growth 
suppressor at all concentrations and, as with DU145 cells, was superior to the silibinin or silymarin mixtures. 
However, LNCaP cells were generally less sensitive to growth inhibition by pure compounds or mixtures than 
either DU145 or PC3 cells. Taken together, isosilybin B was the most potent growth inhibitory constituent of 
silymarin-based milk thistle extracts and was often more effective than silibinin or silymarin mixtures. 
 
Antiproliferative effect of other milk thistle components 
Among the other flavonolignans, silychristin, but not isosilychristin, inhibited DU145 and PC3 cell growth 
(Table 2). This observation is suggestive that the positioning of the 1'-linkage in silychristin is critical for 
antiproliferative activity. It is notable that this linkage in silychristin is shared by the four primary 
flavonolignans but not by the inactive isosilychristin (Fig. 1). 
 
Interestingly, silydianin was slightly growth inhibitory only in androgen-independent DU145 and PC3 cells but 
not in androgen-dependent LNCaP cells. Finally, the flavonoid taxifolin (also known as dihydroquercetin), 
which constitutes the flavonoid moiety in many of these flavonolignans, also inhibited growth in all three cell 
types, with PC3 being more sensitive than either DU145 or LNCaP. Given this observation, we also tested the 
growth inhibitory activity of the corresponding lignan moiety of the bifunctional flavonolignans by exposing 
cells to coniferyl alcohol; however, this compound was without growth inhibitory activity at concentrations up 
to 200 µmol/L in DU145 cells (data not shown). 
 
Cell cycle effects of milk thistle components 
Silibinin is known to cause G1 arrest in most prostate cancer cell lines (7, 24). To determine how the four major 
flavonolignans influenced cell cycle progression, FACS analysis was done on DU145 cells treated in duplicate 
for 72 hours with silybin A, silybin B, isosilybin A, isosilybin B, and silibinin at 60 and 90 µmol/L (Table 3). 
At 60 µmol/L, only silybin B exerted a modest but significant G1 arrest on DU145 cells (6-7% increase relative 
to vehicle control), whereas the other compounds had no appreciable effect. At 90 µmol/L, silybin B led to a 
greater (11-14%) increase in the G1 population (relative to control) followed by isosilybin B and isosilybin A. 
The slight effect of silybin A on the G1 population at this concentration failed to achieve statistical significance. 
With silibinin treatment, the percent of cells accumulating in G1 increased roughly by the average of that for 
silybin A and silybin B, consistent with the demonstration that silibinin comprises nearly equivalent amounts of 
each compound. Most notable was that silybin B had the most pronounced effects on the cell cycle whereas 
being the least effective in growth inhibition of DU145 cells. However, the other compounds and silibinin all 
exhibited a small but reproducible degree of subdiploid DNA fragmentation at 90 µmol/L. This observation is 
consistent with a weak apoptotic effect that does not seem shared by silybin B. 
 
 
NOTE: Exponentially growing DU145 cells were treated with the indicated compounds/mixtures at 60 or 90 
µmol/L for 72 hours. Final DMSO concentrations were 0.09% (v/v) in all samples. The results are presented as 
the mean percent and SD of triplicate samples in each cell cycle phase. 
* Statistically significant differences from the DMSO control group (P < 0.001). 
* Statistically significant differences from the DMSO control group (P < 0.01).  
* Statistically significant differences from the DMSO control group *(P < 0.05). 
DNA topoisomerase II promoter inhibition by milk thistle components in DU145 cells 
The growth inhibitory action of milk thistle extracts and pure compounds would be consistent with suppressed 
expression of topo II , a nuclear enzyme required for chromosomal segregation whose DNA-decatenating 
activity is indispensable for cellular proliferation (31). However, this variable had not been investigated 
previously even for milk thistle extract mixtures, thereby providing an opportunity for these agents to be 
assessed for their action on a transcriptional target. A human topo II promoter-reporter plasmid, -
562TOP2LUC, in which a section of the 5'-flanking region of the topo II gene was subcloned upstream of the 
firefly luciferase cDNA (35), was used to analyze the effect of the individual flavonolignans on promoter 
activity. 
 
The effects of each of the seven flavonolignans, taxifolin, silibinin, and three preparations of silymarin were 
compared at 30 and 60 µmol/L on DU145 cells transiently transfected with this construct. As illustrated in Fig. 
3A, all four of the major flavonolignans had suppressive effects on topo II gene promoter activity. However, 
only the suppression with isosilybin A and isosilybin B achieved statistical significance, with isosilybin B the 
most potent and effective. Silibinin and the three silymarin formulations had comparable topo II promoter 
suppression activities that were intermediate compared with the active pure flavonolignans. In contrast, 
silydianin, silychristin, isosilychristin, and taxifolin lacked any suppressive effect on promoter activity (Fig. 3B) 
despite the fact that silychristin and taxifolin exhibited growth inhibitory effects on these cells (Table 2). 
 
Figure 3. Milk thistle extracts and pure compounds suppress the activity of the human topo II gene promoter in 
DU145 prostate carcinoma cells. The topo II promoter-reporter construct -562TOP2LUC was transiently 
transfected into DU145 cells and samples exposed to the indicated concentrations of extracts and pure 
compounds for 24 hours as described in Materials and Methods. Expressed relative to the mean reporter 
expression of DMSO vehicle control-treated cells (5.28 ± 0.45 x 10
6
 relative light units). A, four major 
flavonolignans silybin A, silybin B, isosilybin A, and isosilybin B. B, silydianin, silychristin, isosilychristin, and 
taxifolin. C, silibinin and the three silymarin preparations (A, Aldrich; M, Madaus; I, Indena). Untreated and 
DMSO controls as means and SD of six replicates; experimental samples as means and SD of three replicates. 
All samples, except untreated controls, contained 0.06% (v/v) DMSO. Statistically significant differences from 
the DMSO controls are noted as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
The rank order of potency of the four most active flavonolignans on topo II promoter activity was determined in 
subsequent experiments with each at 30, 60, 90, or 120 µmol/L. In this case, each of the four compounds 
significantly suppressed topo II promoter activity at concentrations as low as 30 µmol/L (Fig. 4). These results 
deviated somewhat from those observed in Fig. 3A), most likely owing to the greater variability of this transient 
transfection assay relative to other less intrusive methods employed in this study. However, the rank order for 
topo II promoter suppression was comparable: isosilybin B > silybin B > isosilybin A silybin A. Most notable, 
again, was that isosilybin B was the most active of these four compounds. 
 
Figure 4. Isosilybin B is the most potent of the four major flavonolignans in suppressing human topo II gene 
promoter activity in DU145 prostate carcinoma cells. DU145 PCA cells were transiently transfected with - 
562TOP2LUC as described in Materials and Methods. Each replicate set was treated with 30, 60, 90, or 120 
µmol/L purified silybin A, silybin B, isosilybin A, or isosilybin B for 24 hours and processed for luciferase 
activity determinations. Relative to mean reporter expression of DMSO vehicle control-treated cells (2.53 ± 
0.20 x 10
6
 relative light units). Untreated and DMSO controls as means and SD of six replicates; experimental 
samples as means and SD of three replicates. All samples, except untreated controls, contained 0.12% (v/v) 
DMSO. In this case, each flavonolignan treatment group mean was significantly different from the DMSO 
control (P < 0.001, ANOVA, Bonferroni's correction) at all four concentrations tested. This experiment was 
performed twice with similar results. 
 
Flavonolignan inhibition of prostate-specific antigen secretion by LNCaP cells 
PSA is used to monitor androgen action in androgen-dependent prostate carcinoma and serves as a clinical tool 
in screening, diagnosis, and treatment decisions (3). As both silibinin and silymarin have been shown to inhibit 
androgen-induced PSA secretion (34), we examined the relative effects of the major four flavonolignans in 
inhibiting PSA secretion into the culture medium by LNCaP cells (Fig. 5). No appreciable suppression of PSA 
secretion was observed at a concentration of 15 µmol/L for any of the compounds. At 30 µmol/L, both 
isosilybin A and isosilybin B caused a slight reduction in PSA secretion relative to the silybin A and silybin B, 
and these differential effects became more striking at 60 µmol/L. Isosilybin A and isosilybin B reduced PSA 
secretion to nearly undetectable levels at 90 µmol/L, whereas some PSA remained evident with silybin A, 
silybin B, or the silibinin mixture. 
 
Figure 5. The four major milk thistle flavonolignans suppress PSA secretion by LNCaP prostate carcinoma 
cells. LNCaP cells grown in complete RPMI 1640 (10% FCS) were treated with 0, 15, 30, 60, or 90 µmol/L of 
each pure flavonolignan for 24 hours, and medium replaced with serum-free medium containing the same 
respective concentration of each compound. After 48 hours of further incubation, 60 µL of medium from each 
culture were resolved by SDS-PAGE and processed for anti-PSA immunoblotting as described in the Materials 
and Methods. 
 
Discussion 
A major challenge in ascribing biological significance to botanical extracts with potential anticancer activity has 
been their chemical complexity and variability in composition. The work of Agarwal et al. (14, 24, 34) has 
clearly established the potential utility of milk thistle extracts in suppressing prostate cancer cell growth in vitro 
and tumor formation in vivo, with no toxicity to normal prostate epithelium at antitumor concentrations. Most 
studies with milk thistle extracts have used either the crude extract, silymarin, or a semipurified fraction, 
silibinin. Biologists have long regarded silibinin as a pure compound, but evidence existed in the chemistry 
literature as early as 1979 to indicate that it was a diastereomeric mixture (30). It is now appreciated that 
silibinin is roughly a 1:1 mixture of two flavonolignans, silybin A, and silybin B. This mixture clearly possesses 
in vitro and in vivo anticancer activity (14, 24). However, the crude extract silymarin has, in some cases, been 
reported to be more effective than silibinin against cell proliferation or biochemical end points (34). Our recent 
demonstration that silymarin contains five other distinct flavonolignans in addition to the two in silibinin (28) 
provides an opportunity to determine the relative contribution of each component to the anticancer activity 
described for both silibinin and silymarin. 
 
The current studies were initiated to determine whether individual milk thistle components possessed distinct 
biochemical actions that act in concert in the botanical mixture, or whether each compound exhibited similar 
activities with variable potency. With this initial report, it seems that the latter scenario is operating for milk 
thistle flavonolignans toward prostate carcinoma cells in vitro. The four major flavonolignans, when given at 
concentrations high enough, were all capable of arresting the growth of androgen-dependent and androgen-
independent prostate carcinoma cells in vitro. A similar conclusion can be made for cell cycle arrest, topo II 
gene promoter suppression, and inhibition of PSA secretion. However, the summary table (Table 4) reveals 
some notable trends. 
 
Abbreviations: Sily A, Silybin A; Sily B, Silybin B; Iso A, Isosilybin A; Iso B, Isosilybin B. 
 
First, isosilybin B ranked as the most potent flavonolignan for nearly all of the end points evaluated in these 
human prostate carcinoma cell lines. The value of isosilybin B is of interest on several fronts in that it is absent 
from silibinin and composes only 2.1% to 4.4% of the silymarin extracts examined (Table 1). Therefore, this 
low-abundance compound might be the most useful single isomer for in vivo studies or in combination 
experiments using isosilybin B—enriched milk thistle extracts. Second, silybin A was most often the least 
potent of the four major compounds. It composes half of silibinin and is generally the second most abundant 
naturally occurring constituent of crude silymarin extracts. Although silybin A was capable of causing growth 
arrest at higher concentrations, its presence and high abundance may be one reason that in vivo experiments 
with milk thistle extracts require such relatively high doses. Third, silybin B exhibited the most erratic and 
perplexing behavior. Silybin B was the least effective in inhibiting DU145 cell growth but was the most 
effective in causing G1 cell cycle accumulation. One possible explanation for this discrepancy is that the other 
three related flavonolignans may have caused apoptosis preferentially over growth arrest in the cell growth 
inhibition experiments. This scenario is potentially supported by the trend toward increased subdiploid DNA 
distribution observed with the other three major flavonolignans (Table 3). Although these changes did not 
achieve statistical significance, the compounds should be compared in more sensitive and specific biochemical 
assays for their potential proapoptotic effects. 
 
Silybin B also displayed the greatest interexperiment variability in suppressing topo II gene promoter activity 
(compare Fig. 3A with Fig. 4). Part of this discrepancy could be attributed to the more variable nature of 
transient transfection assays relative to others used in this study, yet it was robust enough to reproducibly 
observe isosilybin B as the most potent suppressor of topo II gene promoter activity. Finally, isosilybin A was 
sometimes as potent as isosilybin B (i.e., in PSA suppression) and was at least of intermediate potency on other 
end points. It is worthy to note that isosilybin A is the least water soluble among these four major compounds 
and special care must be exercised when adding it to any aqueous medium. 
 
The anticancer effects of most naturally occurring plant extracts can often be attributed to one compound, such 
as taxol (paclitaxel) in Taxus brevifolia (36), or few compounds, such as camptothecin and 10- 
hydroxycamptothecin in Camptotheca acuminata (37). The current studies were initiated to determine which 
compounds are responsible for documented antiproliferative effects of milk thistle extracts. Interestingly, none 
of the four most closely related milk thistle compounds was devoid of activity on any of the end points tested 
thus far. Several other compounds, such as taxifolin and silychristin, also possessed antiproliferative activity 
when used at higher exposure concentrations. This is perhaps a reflection that each end point (cell proliferation, 
PSA secretion) results from upstream contributions by a number of discrete molecular events. The question 
remaining is whether each milk thistle compound possesses unique effects on these more discrete events (such 
as CDK activity, CDKI levels and localization, cyclin levels), or whether each of the compounds exhibit some 
range of graded responses on common biochemical targets. Some distinctions are already apparent which 
suggest that some compounds may have effects distinct from others; for example, whereas silychristin and 
taxifolin inhibited DU145 cell growth, neither compound suppressed activity of the topo II promoter at growth 
inhibitory concentrations. Because the human topo II gene is subject to regulation by the CDKI, p21 
Cip1
 (38), it 
is possible that only a subset of growth-inhibitory milk thistle compounds can trigger p21 induction. 
 
The potential use of plant-derived chemopreventive agents is clearly influenced by the extent to which the 
active compounds are bioavailable. The primary challenge is whether concentrations observed to be effective in 
vitro can be achieved in vivo. Singh et al. (14) have shown in a dietary feeding study of silibinin to SCID mice 
harboring DU145 xenografts that antitumor effects correlated with plasma concentrations of 14 to 27 µmol/L 
total silibinin. In that study, the authors also reported that the silibinin consumption in the two dosage groups 
ranged from 1.8 to 3.5 mg/d. With typical allometric scaling to a 70-kg human, this consumption correlates 
roughly to a daily dose of 650 to 1,300 mg silibinin. However, direct human pharmacokinetic studies with milk 
thistle extracts are few and difficult to interpret because the formulation used can dramatically affect 
bioavailability (39, 40), and only one study (41) has attempted to follow individual concentrations of pure 
stereoisomers. For instance, in a study of nine healthy male volunteers given a phosphatidylcholine-silibinin 
formulation (IdB 1016; corresponding to 120 mg silibinin, bid) for 8 days, median peak plasma levels of 
unconjugated total silibinin ranged from 0.14 to 7.8 µmol/L across individuals (42). The safety profile of milk 
thistle extracts is suggestive that higher doses can be given that will produce plasma concentrations consistent 
with the effects observed in this report. Moreover, identification of isosilybin B as the most potent prostate 
carcinoma growth inhibitor indicates that any subsequent preclinical or phase I trials should include extracts 
enriched for this component and that each isomer should be monitored separately. Continued study of the 
biological effects of milk thistle flavonolignan isomers should shed greater light on the potential clinical utility 
of these compounds. 
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